Floatz logo

Trastuzumab Deruxtecan

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

National Cancer Institute (NCI)antibody_drug_conjugatePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
FLUTICASONE
Mayo Clinic
Phase 1/2CCC
Sargramostim
Mayo Clinic
Phase 1/2CCC
FILGRASTIM
Mayo Clinic
Phase 1/2CCC
Polyiclc
Mayo Clinic
Phase 1/2CCC
Sonidegib
Mayo Clinic
Phase 1CC
Zn-C3
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →